Amgen to Pay $762 Million Settlement on Drug Marketing

Tuesday, 18 Dec 2012 05:58 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Amgen will pay $762 million to settle litigation that accuses the drugmaker of marketing the anemia drug Aranesp for unapproved uses.

A law firm involved in the case says the Thousand Oaks, Calif., company will pay a $612 million civil settlement, $136 million in criminal fines and a $14 million forfeiture.

Amgen Inc. says it entered a conditional guilty plea to a misdemeanor count of misbranding Aranesp. The company took a $780 million charge last year for a possible settlement.

Amgen develops biologic medicines, or drugs produced by living cells rather than by mixing chemicals. Its settlement marks the latest between the U.S. Department of Justice and a drugmaker over improper marketing allegations.

Doctors can prescribe drugs for unapproved uses, but companies aren't allowed to market drugs for those uses.

© Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
You May Also Like
Around the Web

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved